Key result
Adding Cytoflavin to standard therapy reduces mortality and improves functional recovery in acute ischemic stroke.
Why the study?
Does Cytoflavin added to standard therapy improve clinical outcomes in adult patients in the acute phase of ischemic stroke?
Meta-Analysis
Does Cytoflavin added to standard therapy improve clinical outcomes in adult patients in the acute phase of ischemic stroke?
p-value: p=<0.001
The addition of Cytoflavin to standard therapy may improve mortality and functional outcomes in the acute phase of ischemic stroke, though interpretation is limited by high heterogeneity across studies.
OBJECTIVE: To evaluate the effectiveness of Cytoflavin in conjunction with standard therapy compared to standard therapy alone in patients presenting during the acute phase of ischemic stroke (IS). MATERIAL AND METHODS: A systematic literature review and meta-analysis were conducted to assess the efficacy of Cytoflavin (containing inosine, nicotinamide, riboflavin, and succinic acid; STPF POLYSAN, Ltd., Russia) in adult patients diagnosed with IS. The analysis encompassed both randomized and non-randomized controlled trials, assessing outcomes such as hospital mortality, neurological deficit (measured using the National Institutes of Health Stroke Scale, NIHSS), and functional outcomes (assessed using the modified Rankin Scale and Barthel Index). RESULTS: <0.001). Furthermore, there was a notable improvement in the regression of neurological deficits during the acute phase of IS, as evidenced by higher NIHSS scores and better functional outcomes (Barthel Index) in patients receiving Cytoflavin. CONCLUSION: The findings from this systematic review and meta-analysis indicate that the addition of Cytoflavin to standard therapy for ischemic stroke is associated with more favorable clinical outcomes, including decreased mortality, diminished neurological impairment, and improved functional outcomes at the end of the IS acute phase. It is imperative to consider the high heterogeneity in the functional scales data across studies when interpreting these effects.
No takes yet. Share an insight, caveat, or question.
Алашеев et al. (2026) conducted a meta-analysis in Acute phase of ischemic stroke. Cytoflavin in conjunction with standard therapy vs. Standard therapy alone was evaluated on Hospital mortality, neurological deficit (NIHSS), and functional outcomes (modified Rankin Scale and Barthel Index) (p=<0.001). Cytoflavin added to standard therapy for acute ischemic stroke was associated with decreased mortality, diminished neurological impairment, and improved functional outcomes (P<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: